Introduction and Aim: Graves ophthalmopathy is one of the pandemic public health disorders in Iraq. The current investigation attempts to determine the variation in the complete total blood cells on the recovery of individuals with Graves' ophthalmopathy following low and high-dose Radioactive Iodine 131 (RI-131) exposures.   Materials and Methods: The complete blood CBC level in people with Graves' illness and healthy, normal controls were quantitatively identified using the CBC counter. Thyroid stimulating hormone was utilized to compare the recovery of ophthalmopathy patients in comparison to a control group.    Results: In comparison to healthy controls, patients with Graves' ophthalmopathy disease who received 10 mci of RAI-131 had elevated lymphocyte counts (P<0.01). After one year of therapy with antithyroid drugs, lymphocyte counts rose significantly (P<0.01). In contrast, patients treated with 10 mci of RAI-131 experienced a dramatic reduction in monocytes (P< 0.01) over the course of four months. Lymphocytes, monocytes, and platelets were significantly lower in patients with ophthalmopathy after one month of therapy with 20 mci of RAI-131 compared to controls. No significant difference in red blood cells and hemoglobin levels before and after treatment with low and high doses of RAI-131 was observed.    Conclusion: Assessment of lymphocytes, monocytes, granulocytes, and platelets levels in Graves' ophthalmopathy disease patients (GD ophthalmopathy) could be used as an effective diagnostic marker for determining the most effective dose for Graves' ophthalmopathy disease treatment.